Get the Stockscreener App
31.05
3.32%
0.9307
Vtv Therapeutics Inc stock is traded at $31.05, with a volume of 27,743.
It is up +3.32% in the last 24 hours and down -5.35% over the past month.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
See More
Previous Close:
$30.12
Open:
$29.93
24h Volume:
27,743
Relative Volume:
0.38
Market Cap:
$123.60M
Revenue:
$36.84M
Net Income/Loss:
$-729.00K
P/E Ratio:
-33.62
EPS:
-0.9237
Net Cash Flow:
$-10.02M
1W Performance:
-9.24%
1M Performance:
-5.35%
6M Performance:
-15.71%
1Y Performance:
+101.55%
1-Day Range:
$29.48
$31.41
1-Week Range:
$28.76
$36.52
52-Week Range:
$14.55
$44.00
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Name
Vtv Therapeutics Inc
Sector
Industry
Phone
336-841-0300
Address
3980 PREMIER DR, HIGH POINT, NC
Compare VTVT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
31.26 | 119.09M | 36.84M | -729.00K | -10.02M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
515.31 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.34 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Initiated | Evercore ISI | Outperform |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Jan-05-26 | Initiated | TD Cowen | Buy |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| May-30-19 | Initiated | H.C. Wainwright | Buy |
| Apr-10-18 | Downgrade | Stifel | Buy → Hold |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-08-18 | Initiated | Northland Capital | Outperform |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Sep-04-15 | Initiated | Canaccord Genuity | Buy |
| Aug-24-15 | Initiated | Piper Jaffray | Overweight |
| Aug-24-15 | Initiated | Stifel | Buy |
View All
Vtv Therapeutics Inc Stock (VTVT) Latest News
The Technical Signals Behind (VTVT) That Institutions Follow - Stock Traders Daily
vTv Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HC Wainwright Lowers Earnings Estimates for vTv Therapeutics - MarketBeat
vTv Therapeutics Inc (VTVT) Reports Q2 Loss of $1.05 Per Share -- What Does a GF Score of 26/100 Indicate? - GuruFocus
vTv Therapeutics Inc (VTVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
vTv Therapeutics (NASDAQ:VTVT) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
vTv Therapeutics Inc (VTVT) Stock News Today - TradingKey
vTv Therapeutics Inc (NASDAQ: VTVT) Share Price, VTVT Stock News, VTVT Share Price & Updates - Kalkine
vTv Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
vTv Therapeutics (VTVT) Advances Diabetes Treatment Amid High Pr - GuruFocus
VTVT Maintains Buy Rating -- Price Target Lowered to $42.00 by H - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Price Target Lowered to $42.00 at HC Wainwright - MarketBeat
VTv Therapeutics: Q2 Earnings Snapshot - marketscreener.com
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTV THERAPEUTICS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $42 FROM $45 - Bitget
VTVT Q2'26 Earnings: revenue estimate is 333.33K USD - TradingView
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Precision Trading with Vtv Therapeutics Inc. (VTVT) Risk Zones - Stock Traders Daily
vTv Therapeutics (VTVT) Edges Down 1% to $32.35, Holding Gains Above Key SupportMotive Wave - dars.gov.et
vTv Therapeutics (NASDAQ:VTVT) Shares Pass Above Fifty Day Moving AverageHere's What Happened - marketbeat.com
vTv Therapeutics Inc. Revenue Breakdown – NASDAQ:VTVT - TradingView
vTv Therapeutics Inc (VTVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
vTv Therapeutics (VTVT): Millennium entities disclose 6.9% ownership of Class A shares - Stock Titan
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
vTv Therapeutics Grants Employees Options With 4-Year Vesting - Stock Titan
vTv Therapeutics Inc (VTVT) Cash Flow - TradingKey
vTv Therapeutics Inc (VTVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
vTv Therapeutics Inc (VTVT) Balance Sheet - TradingKey
vTv Therapeutics Inc (VTVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VTVT|vTv Therapeutics Inc|Price:31.030|Chg%:+0.300 - TradingKey
vTv Therapeutics Inc (VTVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
vTv Therapeutics Inc (VTVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
vTv Therapeutics (VTVT) Fades 2.9% as Cautious Trading Prevails Near Key ResistanceWeak Sell Signals - dars.gov.et
vTv Therapeutics, Inc. Class A Revenue Breakdown – SWB:5VT0 - TradingView
TradingKey - TradingKey
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Technical Reactions to VTVT Trends in Macro Strategies - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT) - The Globe and Mail
VTVT Maintains Buy Rating by BTIG -- Price Target Raised to $57. - GuruFocus
vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
MSN Money - MSN
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Recurring Items, Stock DeclinesRevenue Guidance Range - DonanımHaber
vTv Therapeutics lures two employees with 12,500 stock options - Stock Titan
vTv Therapeutics Shareholders Approve Directors, Question Executive Pay - The Globe and Mail
Trading the Move, Not the Narrative: (VTVT) Edition - Stock Traders Daily
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates vTv Therapeutics stock with buy rating - Investing.com
Enterprise value to EBITDA forward of vTv Therapeutics Inc. – NASDAQ:VTVT - TradingView
Vtv Therapeutics Inc Stock (VTVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):